Bayer’s Xarelto patent struck down by German court

German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

‘Always new twists’: Bayer legal team on defending a $4bn drug

31 March 2025 With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

EPO upholds Bayer's Xarelto dosage patents

4 November 2021 Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto.